BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

BRKB

479

-0.55%↓

BRKA.US

719,270

-0.6%↓

JPM

288.78

-0.78%↓

V

301.63

-1.09%↓

MA

494.52

-1.73%↓

Search

Grupo Cibest SA

Fermé

SecteurFinance

70.41 2.85

Résumé

Variation du prix de l'action

24h

Actuel

Min

69.66

Max

71.55

Chiffres clés

By Trading Economics

Revenu

327B

2.2T

Ventes

1T

12T

P/E

Moyenne du Secteur

8.883

54.048

BPA

1.77

Rendement du dividende

9.07

Marge bénéficiaire

20.232

Employés

33,951

EBITDA

-1.3T

2T

Recommandations

By TipRanks

Recommandations

Vente

Prévisions sur 12 Mois

+4.36% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

9.07%

4.84%

Prochains Résultats

4 mai 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-3.2B

18B

Ouverture précédente

67.56

Clôture précédente

70.41

Sentiment de l'Actualité

By Acuity

50%

50%

160 / 441 Classement par Finance

Score Technique

By Trading Central

Confiance

Bearish Evidence

Grupo Cibest SA Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

23 mars 2026, 23:47 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mars 2026, 22:55 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mars 2026, 21:51 UTC

Acquisitions, Fusions, Rachats

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mars 2026, 23:59 UTC

Market Talk

Global Equities Roundup: Market Talk

23 mars 2026, 23:59 UTC

Market Talk

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mars 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mars 2026, 23:37 UTC

Market Talk

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Global Equities Roundup: Market Talk

23 mars 2026, 22:42 UTC

Market Talk
Principaux Événements d'Actualité

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mars 2026, 22:40 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mars 2026, 22:23 UTC

Market Talk

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mars 2026, 22:22 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mars 2026, 22:21 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mars 2026, 22:20 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mars 2026, 22:19 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mars 2026, 22:18 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mars 2026, 22:15 UTC

Acquisitions, Fusions, Rachats

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mars 2026, 22:08 UTC

Market Talk

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mars 2026, 21:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

23 mars 2026, 21:42 UTC

Market Talk

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mars 2026, 21:32 UTC

Résultats

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mars 2026, 21:10 UTC

Principaux Événements d'Actualité

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mars 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

23 mars 2026, 20:50 UTC

Market Talk
Résultats
Principaux Événements d'Actualité

Basic Materials Roundup: Market Talk

Comparaison

Variation de prix

Grupo Cibest SA prévision

Objectif de Prix

By TipRanks

4.36% hausse

Prévisions sur 12 Mois

Moyen 72 USD  4.36%

Haut 76 USD

Bas 68 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Vente

2 ratings

0

Achat

1

Maintien

1

Vente

Score Technique

By Trading Central

40.67 / 41.41Support & Résistance

Court Terme

Bearish Evidence

Moyen Terme

Weak Bearish Evidence

Long Terme

Bullish Evidence

Sentiment

By Acuity

160 / 441Classement par Finance

Sentiment de l'Actualité

Neutral

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

help-icon Live chat